The First Case Report of Effective Treatment With Sotorasib for Metastatic Atypical Lung Carcinoid Harboring KRAS G12C Mutation and Aggressive Disseminated Lung Metastasis: A Case Report

IF 3 Q2 ONCOLOGY

JTO Clinical and Research Reports Pub Date : 2024-01-01 DOI:10.1016/j.jtocrr.2023.100620

Masafumi Saiki MD , Chisa Omori MD , Honami Morikawa MD , Ken Shinohara MD , So Shimamura MD , Hiroki Ohkoshi MD , Yoshinori Uchida MD , Tomohiro Inoue MD, PhD , Tetsuo Kondo MD, PhD , Shinnosuke Ikemura MD, PhD , Kenzo Soejima MD, PhD

{"title":"The First Case Report of Effective Treatment With Sotorasib for Metastatic Atypical Lung Carcinoid Harboring KRAS G12C Mutation and Aggressive Disseminated Lung Metastasis: A Case Report","authors":"Masafumi Saiki MD , Chisa Omori MD , Honami Morikawa MD , Ken Shinohara MD , So Shimamura MD , Hiroki Ohkoshi MD , Yoshinori Uchida MD , Tomohiro Inoue MD, PhD , Tetsuo Kondo MD, PhD , Shinnosuke Ikemura MD, PhD , Kenzo Soejima MD, PhD","doi":"10.1016/j.jtocrr.2023.100620","DOIUrl":null,"url":null,"abstract":"<div><p>Pulmonary neuroendocrine tumors are rare, accounting for approximately 1% to 2% of lung cancers. Atypical carcinoids account for approximately 10% of pulmonary neuroendocrine tumors and are categorized as moderately malignant. Treatment options for advanced-stage atypical carcinoids include everolimus, cytotoxic anticancer agents, and peptide receptor radionuclide therapy. In this report, we present the first case of KRAS G12C mutation-positive atypical carcinoid that was successfully treated with sotorasib. Therapeutically important mutations observed in non-small cell lung cancer are seldom found in atypical carcinoid tumors. Nonetheless, it is worthwhile to search for genetic mutations in atypical carcinoid tumors, considering the potential for molecular targeted therapy to be effective in their treatment as well.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364323001637/pdfft?md5=7b3bfdd3cada44c5ed61bb8d9850418c&pid=1-s2.0-S2666364323001637-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666364323001637","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Pulmonary neuroendocrine tumors are rare, accounting for approximately 1% to 2% of lung cancers. Atypical carcinoids account for approximately 10% of pulmonary neuroendocrine tumors and are categorized as moderately malignant. Treatment options for advanced-stage atypical carcinoids include everolimus, cytotoxic anticancer agents, and peptide receptor radionuclide therapy. In this report, we present the first case of KRAS G12C mutation-positive atypical carcinoid that was successfully treated with sotorasib. Therapeutically important mutations observed in non-small cell lung cancer are seldom found in atypical carcinoid tumors. Nonetheless, it is worthwhile to search for genetic mutations in atypical carcinoid tumors, considering the potential for molecular targeted therapy to be effective in their treatment as well.

查看原文本刊更多论文

索托拉西布有效治疗携带KRAS G12C突变的转移性非典型肺类癌和侵袭性肺播散转移的首例病例报告；病例报告

肺神经内分泌肿瘤十分罕见，约占肺癌的 1%至 2%。非典型类癌约占肺神经内分泌肿瘤的 10%，属于中度恶性肿瘤。晚期非典型类癌的治疗方案包括依维莫司、细胞毒性抗癌药和肽受体放射性核素疗法。在本报告中，我们介绍了首例KRAS G12C突变阳性的非典型类癌，该患者成功接受了索托拉西布治疗。在非小细胞肺癌中观察到的具有重要治疗意义的突变很少出现在非典型类癌中。尽管如此，考虑到分子靶向疗法在治疗非典型类癌中的潜在疗效，在非典型类癌中寻找基因突变是值得的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JTO Clinical and Research Reports Medicine-Oncology

CiteScore

4.20

自引率

0.00%

发文量

145

审稿时长

19 weeks